Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Alan Lamont"'
Autor:
Alan Lamont
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de1454462ed2d58a6faabeaddbe5cadd
https://doi.org/10.2139/ssrn.4162556
https://doi.org/10.2139/ssrn.4162556
Autor:
Michael H Neale, Rosanne Allerton, Federica Di Nicolantonio, Louise A. Knight, Ian A. Cree, Christian M. Kurbacher, Richard J Osborne, Alan Lamont, Geraldine E Skailes
Publikováno v:
Anti-Cancer Drugs. 13:625-630
Liposomal doxorubicin (Caelyx/Doxil) has been shown to be active in around 20% of recurrent ovarian cancers. As yet, there is little clinical data on combinations of existing agents with liposomal doxorubicin, despite considerable clinical experience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::139dc6f9abe98941a88c779049ffaf54
https://doi.org/10.1097/00001813-200207000-00009
https://doi.org/10.1097/00001813-200207000-00009
Autor:
Peter Harper, LE James, Stephen G. Spiro, Robin M. Rudd, Alan Lamont, N.H. Gower, Robert L. Souhami, Mary-Carmen Ruiz de Elvira
Publikováno v:
JNCI Journal of the National Cancer Institute. 89:577-580
Background: Oral etoposide is an active single agent in small-cell lung cancer (SCLC) and is widely prescribed as first-line treatment as an alternative to intravenous combination chemotherapy in patients with extensive disease. Purpose: The intentio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3c58c73199a3ccea973f1308c6e2757
https://doi.org/10.1093/jnci/89.8.577
https://doi.org/10.1093/jnci/89.8.577
Publikováno v:
All Days.
This paper describes the equipment and techniques that were used for a high-pressure, high-temperature (HPHT) cleanout operation carried out on the Shearwater platform in the UK central North Sea with the support of a jackup drilling unit. The projec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dcb09e20077f607139fe25b03399cd3
https://doi.org/10.2118/113782-ms
https://doi.org/10.2118/113782-ms
Publikováno v:
Anti-cancer drugs. 18(9)
The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::538c3ae4bcd65d2c6c13dd6ffa27d111
https://pubmed.ncbi.nlm.nih.gov/17704660
https://pubmed.ncbi.nlm.nih.gov/17704660
Autor:
Sharon Glaysher, Sanjay Sharma, Louise A. Knight, Alan Lamont, Jeremy Hurren, Stuart Mercer, Pauline A. Whitehouse, Ian A. Cree, Federica Di Nicolantonio, John L. Hungerford
Publikováno v:
Anti-cancer drugs. 17(6)
Imatinib mesylate is a specific inhibitor of the Bcr-Abl protein tyrosine kinase that competes with ATP for its specific binding site in the kinase domain. It has activity against platelet-derived growth factor receptor alpha and beta (PDGFR-alpha an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::590bd8e67317fb987172375e684139d1
https://pubmed.ncbi.nlm.nih.gov/16917210
https://pubmed.ncbi.nlm.nih.gov/16917210
Autor:
Silvana Di Palma, Constantinos Yiangou, Ian A. Cree, Sanjay Sharma, Federica Di Nicolantonio, Jeremy Hurren, Sharon Glaysher, Shaw Somers, Augusta Fernando, Alan Lamont, Penny Johnson, Bernard Higgins, Francis G Gabriel, Pauline A. Whitehouse, Stuart Mercer, Tim J. Gulliford, Louise A. Knight, Simon Toh
Publikováno v:
BMC Cancer, Vol 5, Iss 1, p 78 (2005)
BMC Cancer
BMC Cancer
Background Tumor resistance to chemotherapy may be present at the beginning of treatment, develop during treatment, or become apparent on re-treatment of the patient. The mechanisms involved are usually inferred from experiments with cell lines, as s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d782e3cf0a4a786c8d0af2408883dd0d
http://hdl.handle.net/2318/127007
http://hdl.handle.net/2318/127007
Autor:
Jonathan A. Ledermann, Bois A Du, Gordon C Jayson, J. F. Delaloye, M K B Parmar, Valter Torri, S Wheeler, Claes G. Tropé, Ann Marie Swart, Wendi Qian, G.B. Kristensen, Alan Lamont, Nicoletta Colombo, Irene Floriani
Publikováno v:
University of Manchester-PURE
BACKGROUND: Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdf973dc054e65e2606954154bd879a3
http://hdl.handle.net/10281/26643
http://hdl.handle.net/10281/26643
Autor:
Frances A. Shepherd, Vera Hirsh, Lesley Seymour, C. Debruyne, Michael Smylie, Anna Sadura, Alan Lamont, Heidi Martins, Maciej Krzakowski, Sheldon Rubin, Giuseppe Giaccone, Andrea Bezjak, Benny Zee
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(22)
PURPOSE: Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC). This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251e466529ce94beea86d0daf2c4b5de
https://pubmed.ncbi.nlm.nih.gov/12670456
https://pubmed.ncbi.nlm.nih.gov/12670456
Autor:
Alan Lamont, Robert Wade, Amy Kwan, Danish Mazhar, S. J. Harland, Peter M. Wilson, Jonathan Shamash, Wendy Ansell, Simon Chowdhury, Thomas Powles, Naveed Sarwar
Publikováno v:
Journal of Clinical Oncology. 32:366-366
366 Background: Patients with stage I testicular seminoma can be managed by surveillance or treated with adjuvant radiotherapy or chemotherapy. Concerns of second malignancies induced by radiotherapy have led to a preference for adjuvant chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5619059c7e06fc288d1c4629fe3e8e02
https://doi.org/10.1200/jco.2014.32.4_suppl.366
https://doi.org/10.1200/jco.2014.32.4_suppl.366